Enzymatic Analysis to Stratify Covid19 Risk


Robert Jenkins (See Profile)




Development, market readiness, clinical trial



The only platform technology that can DIRECTLY screen at scale for aberrant enzyme activity large. It is a game changer.

Our technology gives us an advantage and the opportunity to build upon the economic moat potential that we possess.

An enzyme function test for earlier prognosis in Covid19 means more treatment options and better outcomes.

Clear potential to detect therapeutic targets. Enzymes are a therapeutic target for the therapeutics.

This information is confidential, do not share or copy.

Under evaluation at least till: 14th May

If you want to have more information or you want to review the project, you have to login or register

©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

Aviso de cookies

Log in with your credentials


Forgot your details?

Create Account

Skip to toolbar